Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment.
Encapsulating peritoneal sclerosis (EPS) is rare but, with its high morbidity and mortality, it represents one of the most serious complications of long-term peritoneal dialysis. The pathogenesis of EPS has not been elucidated yet; therefore, there has been a growing interest in establishing appropriate animal models for EPS that would explain the pathogenesis of EPS and verify the efficacy of therapeutic agents targeting pathways such as angiogenesis and/or fibrosis. This brief review provides an update on previously published animal experimental models of EPS. Based on this review, we discuss some aspects of pathogenesis and treatment options in patients with EPS. Experimental models of EPS cannot exactly reproduce human EPS because the latter most likely has a diverse etiology, including the influences of uremia, dialysis, and genetic factors. There is a need for new animal models that would test interventions targeting multiple risk factors while also taking into account putative genetic diversities that most likely are involved in human EPS.
Park
Sun-Hee
SH
Division of Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Kim
Yong-Lim
YL
Lindholm
Bengt
B
D000818:Animals; D006801:Humans; D051379:Mice; D023421:Models, Animal; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010537:Peritoneum / Q000473:pathology*; D051381:Rats; D012307:Risk Factors; D012598:Sclerosis / Q000209:etiology / Q000473:pathology / Q000628:therapy